A survey of precision diagnosis and management capacity of pulmonary embolism in 90 hospitals of China. (10th March 2020)

• Record Type: Journal Article
• Authors: Wang, Dingyi; Shao, Xiang; Lei, Jieping; Zhai, Zhenguo
• Is Part Of: Clinical respiratory journal. Volume 14:Number 7(2020)
• Page Start: 638
• Page End: 644
• Publication Date: 2020-03-10
• Subjects: capacity -- precision medicine -- pulmonary embolism; Respiratory organs -- Diseases -- Periodicals; Respiratory organs -- Periodicals; 616.24
• DOI: 10.1111/crj.13178
• Languages: English
• ISSNs: 1752-6981

Abstract

Abstract: Objective: To conduct a survey of diagnostic facility and therapeutic capability of Pulmonary thromboembolism (PE) in 90 hospitals throughout China. Method: It was a cross‐sectional study among the participating hospitals of the National Key Research & Development Program of China—the Precision Research of Standardized Management and Application of Pulmonary Thromboembolism to obtain the equipment and application of radiological facility to diagnose PE, laboratory tests for thrombophilia, coagulation function and the availability of anticoagulants and thrombolysis agents. Results: CT pulmonary arteriography is capable in all 90 hospitals, 71.11% of the hospitals could perform ventilation/perfusion scintigraphy, 24.44% of the hospitals do not routinely perform right heart evaluation by echocardiography. Protein C and protein S activity can be detected in half of the hospitals and warfarin pharmacogenomics tests can be conducted in 40 hospitals. Immune turbidimetry was used as the detection method of D‐dimer in 72.37% hospitals. About 81.11% of participating hospitals were equipped with new novel oral anticoagulants, all of which were equipped with Rivaroxaban. Conclusion: The hospitals are capable for standardized diagnosis and management PE, while the capability of precise stratification, coagulation function tests, thrombophilia screening and pharmacogenomics requires further improvement.